200 related articles for article (PubMed ID: 11032933)
1. Unrecognized hepatic steatosis and non-alcoholic steatohepatitis in adjuvant tamoxifen for breast cancer patients.
Murata Y; Ogawa Y; Saibara T; Nishioka A; Fujiwara Y; Fukumoto M; Inomata T; Enzan H; Onishi S; Yoshida S
Oncol Rep; 2000; 7(6):1299-304. PubMed ID: 11032933
[TBL] [Abstract][Full Text] [Related]
2. Toremifene-induced fatty liver and NASH in breast cancer patients with breast-conservation treatment.
Hamada N; Ogawa Y; Saibara T; Murata Y; Kariya S; Nishioka A; Terashima M; Inomata T; Yoshida S
Int J Oncol; 2000 Dec; 17(6):1119-23. PubMed ID: 11078796
[TBL] [Abstract][Full Text] [Related]
3. Tamoxifen-induced non-alcoholic steatohepatitis in patients with breast cancer: determination of a suitable biopsy site for diagnosis.
Murata Y; Ogawa Y; Saibara T; Nishioka A; Takeuchi N; Kariya S; Onishi S; Yoshida S
Oncol Rep; 2003; 10(1):97-100. PubMed ID: 12469151
[TBL] [Abstract][Full Text] [Related]
4. Effects of tamoxifen on hepatic fat content and the development of hepatic steatosis in patients with breast cancer: high frequency of involvement and rapid reversal after completion of tamoxifen therapy.
Nishino M; Hayakawa K; Nakamura Y; Morimoto T; Mukaihara S
AJR Am J Roentgenol; 2003 Jan; 180(1):129-34. PubMed ID: 12490491
[TBL] [Abstract][Full Text] [Related]
5. Tamoxifen-induced nonalcoholic steatohepatitis in breast cancer patients treated with adjuvant tamoxifen.
Nemoto Y; Saibara T; Ogawa Y; Zhang T; Xu N; Ono M; Akisawa N; Iwasaki S; Maeda T; Onishi S
Intern Med; 2002 May; 41(5):345-50. PubMed ID: 12058881
[TBL] [Abstract][Full Text] [Related]
6. Fatty liver and transaminase changes with adjuvant tamoxifen therapy.
Liu CL; Huang JK; Cheng SP; Chang YC; Lee JJ; Liu TP
Anticancer Drugs; 2006 Jul; 17(6):709-13. PubMed ID: 16917217
[TBL] [Abstract][Full Text] [Related]
7. [Cirrhosis with non alcoholic steatohepatitis: role of tamoxifen].
Dray X; Tainturier MH; De La Lande P; Marty O; Mallet L
Gastroenterol Clin Biol; 2000 Nov; 24(11):1122-3. PubMed ID: 11139682
[TBL] [Abstract][Full Text] [Related]
8. Follow-up CT findings of tamoxifen-induced non-alcoholic steatohepatitis (NASH) of breast cancer patients treated with bezafibrate.
Ogawa Y; Murata Y; Saibara T; Nishioka A; Kariya S; Yoshida S
Oncol Rep; 2003; 10(5):1473-8. PubMed ID: 12883726
[TBL] [Abstract][Full Text] [Related]
9. Serum leptin levels are associated with tamoxifen-induced hepatic steatosis.
Günel N; Coşkun U; Toruner FB; Sancak B; Yilmaz E; Cengiz O; Elbeg S; Uner A; Ozkan S
Curr Med Res Opin; 2003; 19(1):47-50. PubMed ID: 12661780
[TBL] [Abstract][Full Text] [Related]
10. Tamoxifen induced hepatotoxicity in breast cancer patients with pre-existing liver steatosis: the role of glucose intolerance.
Elefsiniotis IS; Pantazis KD; Ilias A; Pallis L; Mariolis A; Glynou I; Kada H; Moulakakis A
Eur J Gastroenterol Hepatol; 2004 Jun; 16(6):593-8. PubMed ID: 15167162
[TBL] [Abstract][Full Text] [Related]
11. CYP17 polymorphism as a risk factor of tamoxifen-induced hepatic steatosis in breast cancer patients.
Ohnishi T; Ogawa Y; Saibara T; Nishioka A; Kariya S; Fukumoto M; Onishi S; Yoshida S
Oncol Rep; 2005 Mar; 13(3):485-9. PubMed ID: 15706422
[TBL] [Abstract][Full Text] [Related]
12. Incidence and risk factors for non-alcoholic steatohepatitis in females treated with tamoxifen for breast cancer.
Akhondi-Meybodi M; Mortazavy-Zadah MR; Hashemian Z; Moaiedi M
Arab J Gastroenterol; 2011 Mar; 12(1):34-6. PubMed ID: 21429453
[TBL] [Abstract][Full Text] [Related]
13. Different patterns in the risk of newly developed fatty liver and lipid changes with tamoxifen versus aromatase inhibitors in postmenopausal women with early breast cancer: A propensity score-matched cohort study.
Hong N; Yoon HG; Seo DH; Park S; Kim SI; Sohn JH; Rhee Y
Eur J Cancer; 2017 Sep; 82():103-114. PubMed ID: 28651157
[TBL] [Abstract][Full Text] [Related]
14. Incidence and risk factors for non-alcoholic steatohepatitis: prospective study of 5408 women enrolled in Italian tamoxifen chemoprevention trial.
Bruno S; Maisonneuve P; Castellana P; Rotmensz N; Rossi S; Maggioni M; Persico M; Colombo A; Monasterolo F; Casadei-Giunchi D; Desiderio F; Stroffolini T; Sacchini V; Decensi A; Veronesi U
BMJ; 2005 Apr; 330(7497):932. PubMed ID: 15746106
[TBL] [Abstract][Full Text] [Related]
15. Tamoxifen therapy and hepatic steatosis.
Coskun U; Törüner FB; Günel N
Neoplasma; 2002; 49(1):61-4. PubMed ID: 12044063
[TBL] [Abstract][Full Text] [Related]
16. Non-alcoholic steatohepatitis.
Saibara T; Onishi S; Ogawa Y; Yoshida S; Enzan H
Lancet; 1999 Oct; 354(9186):1299-300. PubMed ID: 10520659
[No Abstract] [Full Text] [Related]
17. Tamoxifen-induced transient multifocal hepatic fatty infiltration.
Cai Q; Bensen M; Greene R; Kirchner J
Am J Gastroenterol; 2000 Jan; 95(1):277-9. PubMed ID: 10638597
[TBL] [Abstract][Full Text] [Related]
18. [Mild forms of acute alcoholic liver damage: significance and differential diagnosis].
Linhart P; Kommerell B; Vereschild N
Dtsch Med Wochenschr; 1973 May; 98(19):983-8. PubMed ID: 4701111
[No Abstract] [Full Text] [Related]
19. Hepatic toxicity caused by adjuvant CMF/CNF in breast cancer patients and reversal by tamoxifen.
Hirvikoski PP; Kumpulainen EJ; Johansson RT
Breast Cancer Res Treat; 1997 Jul; 44(3):269-74. PubMed ID: 9266107
[TBL] [Abstract][Full Text] [Related]
20. A case-control study of non-alcoholic fatty liver disease in breast cancer.
Bilici A; Ozguroglu M; Mihmanli I; Turna H; Adaletli I
Med Oncol; 2007; 24(4):367-71. PubMed ID: 17917083
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
